Deals channel feed – Endpoints News

Deals channel feed

When will Biogen finally pull the trigger on a blockbuster M&A deal?

8 years ago

Women’s health biotech KaNDy dickering with Allergan about a $400M buyout deal — report

8 years ago

Idera, Biocryst to merge, rebrand and focus in rare disease programs

8 years ago

Celgene bags CAR-T player Juno in $9B buyout as biotech M&A suddenly explodes

8 years ago

Diving deep into the hemophilia market, Sanofi strikes an $11.6B Bioverativ buyout

8 years ago

Biogen, UCB step up to kick the tires at Acorda as buyout buzz grows — report

8 years ago

Is Juno worth a $10B-$12B buyout price? Analysts see megabucks deal in the making on reported Celgene talks

8 years ago

Charles River buys KWS BioTest for $20M, gaining immunology discovery capacity and a UK footprint

8 years ago

Novo Nordisk tries to tackle Ablynx and bring it into the fold with a $3B buyout offer, but the biotech keeps saying no

8 years ago

Developing a Sanofi cast-off, Impact Biomedicines now subject of $7B Celgene acquisition deal

8 years ago

After resisting a push to the auction block, Acorda preps for a sale and shares shoot up — report

8 years ago

Takeda swoops in to buy stem cell partner TiGenix for $630M, putting it on the threshold of a likely approval

8 years ago

SVB's crystal ball points to big money biotech IPOs, downshift in the torrid pace of venture investing

8 years ago

INC Research and inVentiv Health come under Syneos Health brand in closing chapter of CRO merger

8 years ago

On a deal spree, Mallinckrodt bags Sucampo and two late-stage rare disease drugs for $1.2B

8 years ago

Roche lines up at the FDA's 10-yard line with $1.7B Ignyta buyout

8 years ago

After axing a top drug, Millendo bags a PhII replacement with biotech buyout

8 years ago

Allergan buys an ailing Repros, bagging a women’s health drug for the pipeline

8 years ago

M&A slows to a trickle in 2017, but Big Pharma could be on deck for mega deals

8 years ago

Gilead swoops in with $567M deal to buy CAR-T 2.0 player Cell Design Labs

8 years ago

Analysts’ top 10 biotech takeover targets are concentrated in two key areas

8 years ago

Biopharma's top 10 overseas cash hoards. And what kind of M&A spree would $171B buy?

8 years ago

After all the love and money, analysts speculate that J&J may swoop in with a buyout offer for Genmab

8 years ago

Bluebird bio orchestrates a series of deals and a buyout to guarantee gene therapy manufacturing

8 years ago

First page Previous page 109 110 111112113 114 115 Next page Last page